Publications by authors named "Yutaka Kawaguchi"

Background/aims: Selecting an optimal advanced therapy for ulcerative colitis (UC) is difficult because of the increasing number of available therapies. This study assessed UC patients' preferences for drug profiles in decision-making regarding advanced therapies using conjoint analysis.

Methods: A web-based survey was conducted from October to November 2023 in patients with UC aged ≥ 18 years with prior oral 5-aminosalicylic acid treatment (UMIN000052327).

View Article and Find Full Text PDF

Background: This study is the first clinical trial for a parenteral non-replicating rotavirus vaccine developed using virus-like particle (VLP) technology.

Methods: This open-labeled, randomized, placebo-controlled trial was conducted in two parts: Part A (a first-in-human study in Australian adults) and Part B (ascending dose and descending age in South African adults, toddlers and infants). In Part A, two cohorts of 10 adults were assigned to receive a single intramuscular injection of 1 of 2 escalating dose levels of the rotavirus VLP (Ro-VLP) vaccine (7 μg or 21 μg) or placebo.

View Article and Find Full Text PDF

Aims/introduction: The sodium-glucose cotransporter 2 inhibitor, canagliflozin, reduced kidney failure and cardiovascular events in the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial. We carried out a post-hoc analysis to evaluate the efficacy and safety of canagliflozin in a subgroup of participants in East and South-East Asian (EA) countries who are at high risk of renal complications.

Materials And Methods: Participants with an estimated glomerular filtration rate of 30 to <90 mL/min/1.

View Article and Find Full Text PDF
Article Synopsis
  • Vadadustat is a medication approved in Japan for treating anemia in patients with chronic kidney disease (CKD) who are on hemodialysis and not receiving erythropoiesis-stimulating agents (ESAs).
  • In a phase 3 study, 24 Japanese patients took vadadustat for 24 weeks, starting at a dose of 300 mg/day aimed at maintaining hemoglobin levels between 10.0-12.0 g/dL.
  • The results showed an average hemoglobin level of 10.75 g/dL at the end of the study, with mild side effects like shunt stenosis, diarrhea, and vomiting, indicating it was well-tolerated overall.
View Article and Find Full Text PDF
Article Synopsis
  • The study examined the effectiveness and safety of vadadustat, an oral treatment for anemia, compared to darbepoetin alfa, an injection, in Japanese adults with nondialysis-dependent chronic kidney disease (NDD-CKD).
  • Over 52 weeks, both treatments achieved hemoglobin levels within the target range, with vadadustat showing noninferiority to darbepoetin alfa, meaning it was just as effective.
  • Adverse events were similar for both groups, with common issues for vadadustat being nasopharyngitis, diarrhea, and constipation, indicating it is a potentially well-tolerated option for treating anemia in NDD-CKD patients.
View Article and Find Full Text PDF
Article Synopsis
  • Vadadustat, an oral medication that promotes red blood cell production, was tested against darbepoetin alfa in a Phase 3 study involving Japanese patients on hemodialysis experiencing anemia.
  • After 52 weeks of treatment, vadadustat showed comparable effectiveness in maintaining hemoglobin (Hb) levels within a target range (10.0-12.0 g/dL), meeting the study's primary goal for average Hb levels at specific weeks.
  • Both treatments had similar side effects such as nasopharyngitis and diarrhea, with no new safety issues identified, suggesting vadadustat could serve as a viable alternative to traditional erythropoiesis-stimulating agents for these patients.
View Article and Find Full Text PDF
Article Synopsis
  • * The study lasted 24 weeks, with patients taking an initial dose of 300 mg/day of vadadustat and adjustments made to maintain hemoglobin levels between 11.0-13.0 g/dL.
  • * Results showed that the average hemoglobin level at weeks 20 and 24 was 11.35 g/dL and the treatment was generally well tolerated, with most adverse events (like infections) not linked to the medication, suggesting its effectiveness for this patient group.
View Article and Find Full Text PDF
Article Synopsis
  • * A phase IV study assessed canagliflozin as an additional treatment for Japanese patients with type 2 diabetes who weren't adequately controlled on a GLP-1RA for at least 12 weeks, by monitoring various health indicators for 52 weeks.
  • * Results showed significant improvements in blood sugar levels (HbA1c decreased by 0.70%), weight, blood pressure, and cholesterol, with mild adverse effects reported,
View Article and Find Full Text PDF
Article Synopsis
  • - The study evaluated the long-term effectiveness and safety of canagliflozin as an additional treatment for Japanese patients with type 2 diabetes who were not achieving good blood sugar control with insulin alone.
  • - It involved a 16-week double-blind trial comparing canagliflozin (100 mg) to a placebo, followed by a 36-week period where all participants received canagliflozin, measuring changes in HbA1c levels, weight, and occurrence of side effects.
  • - Results showed that canagliflozin led to significant improvements in blood sugar and weight in both treatment groups, with a notable incidence of mild hypoglycemic events, highlighting its efficacy and acceptable safety profile when used alongside insulin.
View Article and Find Full Text PDF
Article Synopsis
  • - A study was conducted to assess the effectiveness of combining canagliflozin with insulin for Japanese patients with type 2 diabetes, as previous research focused more on Caucasian populations.
  • - Patients who struggled to control their blood sugar levels were divided into two groups: one received canagliflozin alongside their insulin, while the other received a placebo. The main goal was to measure changes in glycated hemoglobin (HbA1c) levels after 16 weeks.
  • - Results showed that those taking canagliflozin experienced a significant reduction in HbA1c levels, lower fasting glucose, decreased body weight, and improved HDL cholesterol, although there was a slightly higher incidence of hypoglycemic events compared to
View Article and Find Full Text PDF

Maintenance of genome stability relies on the accurate repair of DNA double-strand breaks (DSBs) that arise during DNA replication or introduced by DNA-damaging agents. Failure to repair such breaks can lead to the introduction of mutations and chromosomal translocations. Several pathways, homologous recombination, single-strand annealing and nonhomologous end-joining, are known to repair DSBs.

View Article and Find Full Text PDF

Baculovirus expression systems (BES) are widely used for recombinant protein production in lepidopteran cells or larvae. However, even in BES, the insolubility of recombinant proteins sometimes makes their expression difficult. In this study, to improve the solubility and yield of foreign proteins, we constructed transgenic silkworms using silkworm heat-shock proteins, Hsp70 and Hsp40, or Hsc70 and Hsp90 co-chaperone Hop.

View Article and Find Full Text PDF

The telomere structures in Bombyx mori are thought to be maintained mainly by the transposition of the specialized telomeric retroelements SART and TRAS. The silkworm genome has telomeric TTAGG repeats and telomerase, but this telomerase displays little or no activity. Here, we report that the transcription of the telomeric retroelements SART1 and TRAS1 is suppressed by the silkworm Piwi subfamily proteins BmAgo3 and Siwi.

View Article and Find Full Text PDF

Many biological processes are usually coupled to the formation of protein complexes. The yeast two-hybrid system is a powerful tool for analyzing protein-protein interactions. Different patterns of protein modifications, such as glycosylation, phosphorylation, and acetylation, may affect the ability of proteins to interact.

View Article and Find Full Text PDF

Gap junctions that allow for a direct exchange of second messenger and ions are the most conserved cellular structures in multicellular organisms. We have isolated and characterized a Bombyx mori gene innexin3 that encodes a new member of the innexin family required for the early embryonic development. The BmINX3 mRNA was 1,814 nucleotide residues in length, and the deduced amino acid sequence of BmInx3 shared 74% similarity with Apis melifera innexin3.

View Article and Find Full Text PDF

Tetracycline-inducible gene expression (Tet-on) system has become one of the first choices for the control of transgenes expression in mammal and drosophila. However, the Tet-on systems that have been established in mammalian system or tuned into drosophila do not function in the silkworm, Bombyx mori. To construct a functional Tet-on system in B.

View Article and Find Full Text PDF

Cecropins belong to the antibacterial peptides family and are induced after injection of bacteria or their cell-wall components. By silkworm cDNA microarray analysis, a novel type of Cecropin family gene was identified as a cDNA up-regulated in early embryo, 1 day after oviposition. The cDNA isolated was 394 bp with 198 ORF translating 65 amino acids, encoding BmCecropin-E (BmCec-E).

View Article and Find Full Text PDF

The recombinant protein expression by Bombyx mori nucleopolyhedrovirus (BmNPV) infecting silkworm larvae or pupae may endow us with a potent system for the production of large eukaryotic proteins. However, the screening of silkworm strains ideally suited to this method has scarcely been conducted. In the present study, we injected recombinant BmNPV containing a reporter gene, luciferase or DsRed, into hemocoel of fifth instar larvae of selected 12 silkworm strains.

View Article and Find Full Text PDF

The promoter regions of the Bombyx mori HSC70-4 and B. mori TCTP genes characterized previously were used for the construction of a series of constitutive gene expression systems active in cultured cells. The relative abilities of these promoters were evaluated by comparing those of a silkworm actin A3 (BmActin3) promoter, which is used widely as the first choice.

View Article and Find Full Text PDF

The silkworm is a typical holometabolous insect going through drastic morphological changes upon metamorphosis from larvae to pupae. Comprehensive studies focusing on the changes help elucidate understanding of a biogenic mechanism. Here, we report the initial profile of the intersegmental muscle (ISM) proteins of the silkworm during larval-pupal metamorphosis.

View Article and Find Full Text PDF

The silk gland of Bombyx mori is an organ specialized for the synthesis and secretion of silk proteins. We report here the resolution of silk gland proteins by 2-DE and the identification of many of those proteins. This was accomplished by dissecting the glands into several sections, with each exhibiting more than 400 protein spots by 2-DE, of which 100 spots were excised and characterized by in-gel digestion followed by PMF.

View Article and Find Full Text PDF

The argonaute protein family provides central components for RNA interference (RNAi) and related phenomena in a wide variety of organisms. Here, we isolated, from a Bombyx mori cell, a cDNA clone named BmAGO2, which is homologous to Drosophila ARGONAUTE2, the gene encoding a repressive factor for the recombination repair of extrachromosomal double-strand breaks (DSBs). RNAi-mediated silencing of the BmAGO2 sequence markedly increased homologous recombination (HR) repair of DSBs in episomal DNA, but had no effect on that in chromosomes.

View Article and Find Full Text PDF

The integrase from the Streptomyces bacteriophage phiC31 carries out efficient recombination between an attP site in the phage genome and an attB site in the host chromosome. In the present study, we have used the phiC31 integrase system to mediate site-specific recombination in the cultured silkworm cell line BmN4. A plasmid containing a cDNA encoding DsRed flanked by two phiC31 attP sites was co-transfected together with a helper plasmid encoding the phiC31 integrase into a cell line in which phiC31 attB sites inserted between a baculovirus IE2 promoter, and a polyadenylation signal are present in one chromosome.

View Article and Find Full Text PDF

Sonoporation (ultrasound treatment) provides a new and attractive nonviral way of in vivo gene transfer. To access the applicability of this method to the silkworm, Bombyx mori, we have compared the efficiencies of gene transfer by means of lipofection (using an appropriate agent, PDD111), sonoporation (ditto, FluoroGene), and lipofection followed by sonoporation. By these methods, a luciferase expression plasmid was found to be markedly transferred into the haemocoel of newly ecdysed fifth instar silkworm larvae, and also into other tissues although with lower rates compared with the haemocoel.

View Article and Find Full Text PDF